Skip to content

Search

Pediatric sepsis in the developing world.

Sepsis is the leading killer of children worldwide, but this is not reflected in estimates of global mortality.

Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections

This paper reports on treatment, and preventing infection in close contact, of invasive group A streptococcal (iGAS) using the antibiotic clindamycin and...

Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screening

This study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010

Quantification of the disease burden caused by different risks informs prevention by providing an account of health loss different to that provided by a...

Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?

Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and...

Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué

Develop a 'roadmap' of key actions that need to be taken by governments to eliminate ARF and eradicate RHD in Africa

Ending rheumatic heart disease in Australia: the evidence for a new approach

The RHD Endgame Strategy: the blueprint to eliminate rheumatic heart disease in Australia by 2031 (the Endgame Strategy) is the blueprint to eliminate rheumatic heart disease (RHD) in Australia by 2031. Aboriginal and Torres Strait Islander people live with one of the highest per capita burdens of RHD in the world.

Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection

Benzathine penicillin G has been used as monthly deep intramuscular (IM) injections since the 1950s for secondary prevention of acute rheumatic fever and rheumatic heart disease (RHD). Injection frequency and pain are major programmatic barriers for adherence, prompting calls for development of better long-acting penicillin preparations to prevent RHD.